There was a significant correlation for the subset of subjects who showed a significantly greater responder rate in the post hoc analysis of the trial , i.e. , subjects who had a 3-fold or greater increase in average daily seizure frequency perimenstrually compared with the midfollicular and midluteal phases ( C1 3 : r = -0.442 , p = 0.013 , and specifically for C1 3 progesterone-treated subjects [ r = -0.452 , p = 0.035 ] , but not other groups [ C1 3 placebo : r = -0.367 ; C1 < 3 progesterone : r = 0.099 ; C1 < 3 placebo : r = 0.131 ; p = not significant ] ) .